The regulatory agency has granted Priority Review of the NDA and assigned a Prescription Drug User Fee Act target action date of March 19, the biotechnology company said.
Price: 187.09, Change: +2.15, Percent Change: +1.16
|Consensus for Zumiez Q2 Earnings Raised but Full Yea...|
|Williams Sonoma's Q2, 2021, 2022 Full Year Earnings ...|
|Analysts' Ratchet Up 2020, 2021 Consensus Estimates ...|
|Q1, 2021, 2022 Earnings Estimates for Advanced Drain...|
|Q2 Projection for Westlake Chemical Increased but 20...|